New Treatment Paradigms in Atopic Dermatitis : Understanding and Incorporating Recent and Emerging Therapies
WebcastFaculty
OVERVIEW
New Treatment Paradigms in Atopic Dermatitis : Understanding and Incorporating Recent and Emerging Therapies is organized by Global Academy For Medical Education and will be held Jun 01, 2016 - May 31, 2018. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Atopic dermatitis (AD), also called eczema, is a chronic, relapsing inflammatory skin disease that is associated with significant morbidity and costs to patients and their families. AD occurs most often in infants and children, and its onset decreases substantially with age. Approximately 80% of children with atopic dermatitis develop asthma or allergic rhinitis later in childhood. Recent research into the pathophysiology of AD indicates that it has a complex etiology involving multiple immunologic and inflammatory pathways and environmental triggers, as well as mutations in the filaggrin gene in many—but not all—patients. Clinicians need to remain up-to-date on the benefits and risks of all treatment options available as well as make the appropriate selection for their patients. Traditional AD treatments—including topical corticosteroids and topical calcineurin inhibitors—are likely to continue to be important in the management of AD. With the increasing understanding of the role of epidermal skin barrier defects in AD pathogenesis, the importance of moisturization beginning early in life has achieved new prominence. In addition, there is renewed interest in dilute bleach baths as a means of controlling Staphylococcus aureus colonization in selected patients. Evidence shows that this method is both anti–inflammatory and anti–infective. Continuing research will provide insights regarding the optimization of these familiar strategies.
Learning Objectives
At the conclusion of this program, participants should be better able to:
• Discuss the most recent information on the epidemiology and pathogenesis of AD, and how this is likely to affect the management of patients with AD.
• Explain how the current and emerging understanding of filaggrin loss-of-function mutations affect the development of AD.
• Recognize the rationale for and mechanisms of action of existing and emerging therapies for AD.
• Analyze how existing and emerging therapies fit into the AD treatment paradigm.
• More effectively individualize patient treatment strategies by considering the full range of current and emerging therapeutic options.
Additional details will be posted as soon as they are available.
Atopic dermatitis (AD), also called eczema, is a chronic, relapsing inflammatory skin disease that is associated with significant morbidity and costs to patients and their families. AD occurs most often in infants and children, and its onset decreases substantially with age. Approximately 80% of children with atopic dermatitis develop asthma or allergic rhinitis later in childhood. Recent research into the pathophysiology of AD indicates that it has a complex etiology involving multiple immunologic and inflammatory pathways and environmental triggers, as well as mutations in the filaggrin gene in many—but not all—patients. Clinicians need to remain up-to-date on the benefits and risks of all treatment options available as well as make the appropriate selection for their patients. Traditional AD treatments—including topical corticosteroids and topical calcineurin inhibitors—are likely to continue to be important in the management of AD. With the increasing understanding of the role of epidermal skin barrier defects in AD pathogenesis, the importance of moisturization beginning early in life has achieved new prominence. In addition, there is renewed interest in dilute bleach baths as a means of controlling Staphylococcus aureus colonization in selected patients. Evidence shows that this method is both anti–inflammatory and anti–infective. Continuing research will provide insights regarding the optimization of these familiar strategies.
Learning Objectives
At the conclusion of this program, participants should be better able to:
• Discuss the most recent information on the epidemiology and pathogenesis of AD, and how this is likely to affect the management of patients with AD.
• Explain how the current and emerging understanding of filaggrin loss-of-function mutations affect the development of AD.
• Recognize the rationale for and mechanisms of action of existing and emerging therapies for AD.
• Analyze how existing and emerging therapies fit into the AD treatment paradigm.
• More effectively individualize patient treatment strategies by considering the full range of current and emerging therapeutic options.
Additional details will be posted as soon as they are available.
SPECIALITIES
DermatologyRELATED ONLINE COURSES
Quick Links